JP2024515307A5 - - Google Patents

Info

Publication number
JP2024515307A5
JP2024515307A5 JP2023564671A JP2023564671A JP2024515307A5 JP 2024515307 A5 JP2024515307 A5 JP 2024515307A5 JP 2023564671 A JP2023564671 A JP 2023564671A JP 2023564671 A JP2023564671 A JP 2023564671A JP 2024515307 A5 JP2024515307 A5 JP 2024515307A5
Authority
JP
Japan
Prior art keywords
cyclin
polypeptide
seq
nucleic acid
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515307A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2022/050366 external-priority patent/WO2022221922A1/en
Publication of JP2024515307A publication Critical patent/JP2024515307A/ja
Publication of JP2024515307A5 publication Critical patent/JP2024515307A5/ja
Pending legal-status Critical Current

Links

JP2023564671A 2021-04-22 2022-04-22 修飾ポリペプチド及びその使用 Pending JP2024515307A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021901193 2021-04-22
AU2021901193A AU2021901193A0 (en) 2021-04-22 Modified polypeptides and uses thereof
PCT/AU2022/050366 WO2022221922A1 (en) 2021-04-22 2022-04-22 Modified polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
JP2024515307A JP2024515307A (ja) 2024-04-08
JP2024515307A5 true JP2024515307A5 (cg-RX-API-DMAC7.html) 2025-04-23

Family

ID=83723498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564671A Pending JP2024515307A (ja) 2021-04-22 2022-04-22 修飾ポリペプチド及びその使用

Country Status (7)

Country Link
US (1) US20240199713A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326340A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024515307A (cg-RX-API-DMAC7.html)
CN (1) CN117241838A (cg-RX-API-DMAC7.html)
AU (1) AU2022261654A1 (cg-RX-API-DMAC7.html)
CA (1) CA3215808A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022221922A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025007194A1 (en) * 2023-07-05 2025-01-09 Macquarie University Modulation of gene expression
AU2024361525A1 (en) * 2023-10-16 2026-04-30 Infensa Bioscience Pty Ltd Inhibitors and uses therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017353361B2 (en) * 2016-11-07 2024-04-04 Macquarie University Modulation of protein accumulation and uses therefor
US12496327B2 (en) * 2019-01-14 2025-12-16 President And Fellows Of Harvard College Methods and compositions for restoring STMN2 levels

Similar Documents

Publication Publication Date Title
Bayer et al. It all sticks together—the APP-related family of proteins and Alzheimer's disease
AU2009303382B2 (en) Transducible polypeptides for modifying mitochondrial metabolism
JP4838722B2 (ja) ポリヌクレオチドを送達する方法、及び送達用組成物
US10280419B2 (en) Reduction of amyloid beta peptide production via modification of the APP gene using the CRISPR/Cas system
Rehmani et al. Oral delivery of anti-diabetes therapeutics using cell penetrating and transcytosing peptide strategies
EP4286406A1 (en) Fusion molecule having non-inflammatory phagocytosis inducing activity
JP2011503069A5 (cg-RX-API-DMAC7.html)
JP2014520148A (ja) 治療のための神経筋接合部への標的化
US20140113853A1 (en) Transducible Polypeptides for Modifying Metabolism
Lee et al. [6] Purification of paired helical filament tau and normal tau from human brain tissue
AU2003201733A1 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2011162655A1 (en) Compound and method for treatment of alzheimer's disease and familial dementia
JP2021534206A5 (cg-RX-API-DMAC7.html)
WO2024178223A1 (en) Antisense oligonucleotides for preventing unc13a misplicing
Kosik et al. Along the way to a neurofibrillary tangle: a look at the structure of tau
Moriguchi et al. Structure and subcellular localization of a small RNA‐binding protein from tobacco
US9221890B2 (en) Gigaxonin fusion protein and methods for treating giant axonal neuropathy
WO2013103964A1 (en) Methods and compositions for treating proteinopathies
CN115475247B (zh) β2-微球蛋白或其抑制剂的制药用途
US20160340656A1 (en) Peptides derived from gse 24.2 for treating diseases caused by oxidative stress and damage to dna
JP2022552003A5 (cg-RX-API-DMAC7.html)
WO2017189826A1 (en) Use of cell-permeable peptides and non-peptide carriers conjugated with nemo binding domain cargo sequence for the treatment of dry eye disease and uveitis
KR101106262B1 (ko) 인간 호메오 도메인 유전자 유래의 단백질 도입 도메인 및 이를 이용한 단백질 도입 벡터
DE102021107061A1 (de) Verwendung von d-enantiomeren peptidliganden von monomerem a-synuclein für die therapie verschiedener synucleinopathien
CN101525602A (zh) 制备抗pink1多克隆抗血清的多肽及其应用